Literature DB >> 61801

In vitro transmission and propagation of the bovine leukemia virus in monolayer cell cultures.

D C Graves, J F Ferrer.   

Abstract

This study demonstrates that the bovine leukemia virus (BLV) can infect in vitro cells of human, simian, bovine, canine, caprine, ovine, and bat origin. Cultures of these cells, cocultivated with BLV-infected cells or inoculated with cell-free BLV preparations, continuoously showed the presence of cells with the internal BLV antigen as well as BLV-induced syncytia. Virus replication was abundant and increased with passage in bat lung cells and was moderate but constant in fetal canine thymus cells. The amounts of virus released by the simian DBS-FRhL-1 and caprine S-743 cultures were low to moderate during the first 4 to 8 weeks and decreased thereafter. In the infected fetal lamb spleen cell cultures, virus production was low and declined further with passage. Bovine embryonic spleen and human diploid embryonic lung WI-38 cell cultures produced very small amounts of virus only during the first two passages after inoculation despite the fact that they remained infected, as determined by the continuous presence of cell BLV antigen and syncytia. Morphologically and antigenically, the virus particles released by the monolayer cell cultures were indistinguishable from those found in short-term and long-term cultures of BLV-infected bovine lymphoid cells. Repeated electron microscopic examinations and serological tests showed that all the BLV-infected cultures, including those from which the infecting inocula were obtained, were free of the foamy-like bovine syncytial virus, parainfluenza 3 virus, infectious bovine rhinotracheitis virus, bovine viral diarrhea virus, and the maedi-like bovine R-29 virus.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 61801

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

1.  Inhibition of bovine leukemia virus release by antiviral antibodies.

Authors:  D M Driscoll; M Onuma; C Olson
Journal:  Arch Virol       Date:  1977       Impact factor: 2.574

2.  Stability of bovine leukemia virus antigens.

Authors:  S Inumaru; H Oikawa; H Nakajima
Journal:  Can J Vet Res       Date:  1987-01       Impact factor: 1.310

3.  Identification and some biochemical properties of the major XBL gene product of bovine leukemia virus.

Authors:  N Sagata; J Tsuzuku-Kawamura; M Nagayoshi-Aida; F Shimizu; K Imagawa; Y Ikawa
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

4.  An improved syncytia infectivity assay for the bovine leukemia virus.

Authors:  C A Diglio; C E Piper; J F Ferrer
Journal:  In Vitro       Date:  1978-06

5.  Construction of a recombinant bovine leukemia virus vector for analysis of virus infectivity.

Authors:  D Derse; L Martarano
Journal:  J Virol       Date:  1990-01       Impact factor: 5.103

6.  Detection, purification, and characterization of two species of covalently closed circular proviral DNA molecules of bovine leukemia virus.

Authors:  S V Kashmiri; R Mehdi; J F Ferrer
Journal:  J Virol       Date:  1983-03       Impact factor: 5.103

7.  Expression of the bovine leukemia virus X region in virus-infected cells.

Authors:  N R Rice; S L Simek; G C Dubois; S D Showalter; R V Gilden; R M Stephens
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

8.  Transcriptional control of the bovine leukemia virus genome: role and characterization of a non-immunoglobulin plasma protein from bovine leukemia virus-infected cattle.

Authors:  P Gupta; S V Kashmiri; J F Ferrer
Journal:  J Virol       Date:  1984-04       Impact factor: 5.103

9.  In vivo protein binding and functional analysis of cis-acting elements in the U3 region of the bovine leukemia virus long terminal repeat.

Authors:  J Xiao; G C Buehring
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

10.  Ribozyme cleaves rex/tax mRNA and inhibits bovine leukemia virus expression.

Authors:  G H Cantor; T F McElwain; T A Birkebak; G H Palmer
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.